NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today ...

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today ...

Calidi Biotherapeutics Inc. CLDI stock surged by 39.47% in the after-hours trading session on Tuesday. The stock price ...

Calidi Biotherapeutics (NYSE American: CLDI) , a clinical-stage biotech innovator, announced its inclusion in an editorial by NetworkNewsWire titled“ ...

Calidi Biotherapeutics stock was up 171.84% in pre-market trading on Wednesday, following a 39.47% rally yesterday. However, ...

Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease ...

Calidi Biotherapeutics (NYSE American: CLDI) , a clinical-stage biotech firm developing targeted therapies for genetic medicine delivery, announced a ...

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering the development a new generation of targeted immunotherapies.

--Calidi Biotherapeutics Inc., a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to deliver genetic payloads, issued ...

Detailed price information for Calidi Biotherapeutics Inc (CLDI-A) from The Globe and Mail including charting and trades.

SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) ('Calidi”), a clinical-stage biotechnology company pioneering the development of systemic oncolytic ...

About Calidi Biotherapeutics Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering the development a new generation of targeted immunotherapies.